MATERNUS-Kliniken AG (DE:MAK)
XETRA:MAK
Top Page
MATERNUS-Kliniken AG
(XETRA:MAK)
Select Model
Select Model
Rating:41Neutral
Price Target:
€1.00
▲(2.04% Upside)
Action:ReiteratedDate:11/01/25
MATERNUS-Kliniken AG receives an overall stock score of 41, driven primarily by weak financial performance with negative profitability and equity concerns outweighing cash flow improvements. Technical indicators further reflect a bearish trend, and poor valuation metrics add to the cautious outlook.
Positive Factors
Revenue Growth
Consistent revenue growth indicates a stable demand for healthcare services, suggesting resilience in the company's core business model.
Negative Factors
High Financial Leverage
High financial leverage increases financial risk and limits the company's ability to invest in growth or weather economic downturns.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Consistent revenue growth indicates a stable demand for healthcare services, suggesting resilience in the company's core business model.
Read all positive factors
MATERNUS-Kliniken AG (MAK) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€25.79M
Dividend YieldN/A
Average Volume (3M)618.00
Price to Earnings (P/E)―
Beta (1Y)0.51
Revenue Growth6.87%
EPS Growth-94.85%
CountryDE
Employees1,452
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)N/A
Shares Outstanding20,970,000
10 Day Avg. Volume1,293
30 Day Avg. Volume618
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)-0.43
Price to Sales (P/S)0.25
P/FCF Ratio2.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
MATERNUS-Kliniken AG Business Overview & Revenue Model
Company Description
Maternus-Kliniken Aktiengesellschaft operates retirement and nursing homes, rehabilitation clinics, and various service companies that operate in the field of geriatric care and rehabilitation medicine. The company also provides emergency call, as...
How the Company Makes Money
MATERNUS-Kliniken AG generates revenue primarily through patient services and health insurance reimbursements. The company offers a range of medical treatments and rehabilitation services, which are often covered by statutory and private health in...
MATERNUS-Kliniken AG Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
20
Very Negative
Cash Flow
60
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 175.47M | 114.00M | 102.31M | 106.70M | 111.44M | 114.30M |
| Gross Profit | 45.57M | 98.78M | 87.45M | 86.98M | 97.52M | 97.70M |
| EBITDA | 8.46M | 10.71M | 4.71M | 1.71M | 14.96M | 13.21M |
| Net Income | -15.51M | -13.16M | -14.26M | -14.08M | -2.56M | -9.62M |
Balance Sheet | ||||||
| Total Assets | 137.19M | 139.88M | 154.38M | 153.40M | 165.41M | 178.63M |
| Cash, Cash Equivalents and Short-Term Investments | 2.18M | 4.94M | 9.99M | 5.20M | 16.02M | 11.41M |
| Total Debt | 0.00 | 165.41M | 112.35M | 117.81M | 123.65M | 137.16M |
| Total Liabilities | 204.59M | 206.72M | 206.49M | 190.95M | 186.76M | 197.33M |
| Stockholders Equity | -68.94M | -66.84M | -53.76M | -39.30M | -25.34M | -25.41M |
Cash Flow | ||||||
| Free Cash Flow | 9.74M | 13.86M | -1.44M | 2.33M | 15.32M | 11.43M |
| Operating Cash Flow | 9.84M | 15.07M | 2.52M | 4.33M | 17.24M | 12.17M |
| Investing Cash Flow | 48.00K | -1.07M | -3.96M | -2.00M | -1.92M | -702.00K |
| Financing Cash Flow | -11.29M | -11.68M | -69.00K | -12.76M | -12.79M | -2.23M |
MATERNUS-Kliniken AG Technical Analysis
Positive
0.98
Price Trends
1.08
Positive
1.05
Positive
1.11
Positive
Market Momentum
0.05
Positive
52.53
Neutral
16.47
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:MAK, the sentiment is Positive. The current price of 0.98 is below the 20-day moving average (MA) of 1.26, below the 50-day MA of 1.08, and below the 200-day MA of 1.11, indicating a bullish trend. The MACD of 0.05 indicates Positive momentum. The RSI at 52.53 is Neutral, neither overbought nor oversold. The STOCH value of 16.47 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:MAK.
MATERNUS-Kliniken AG Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | €271.95M | 6.07 | 15.83% | 2.80% | 6.52% | 7.17% | |
73 Outperform | €145.80M | 8.54 | 22.77% | ― | 0.21% | 7.53% | |
64 Neutral | €163.40M | 6.90 | 10.71% | 1.12% | 4.90% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | €25.79M | -1.84 | 22.85% | ― | 6.87% | -94.85% |
* Healthcare Sector Average
DE:MAK
MATERNUS-Kliniken AG
1.23
-0.07
-5.38%
DE:MED
MEDICLIN
3.44
0.58
20.28%
DE:LIK
Limes Schlosskliniken AG
486.00
204.00
72.34%
DE:EIF
Eifelhoehen-Klinik AG
3.24
1.84
131.43%
DE:JTH0
Gesundheitswelt Chiemgau AG
12.80
0.72
5.96%
DE:M12
M1 Kliniken AG
14.56
0.17
1.18%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.